BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Klimontov VV, Korbut AI, Taskaeva IS, Bgatova NP, Dashkin MV, Orlov NB, Khotskina AS, Zavyalov EL, Klein T. Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice. World J Diabetes 2020; 11(12): 596-610 [PMID: 33384767 DOI: 10.4239/wjd.v11.i12.596]
URL: https://www.wjgnet.com/1948-9358/full/v11/i12/596.htm
Number Citing Articles
1
Jingshu Sun, Xinyu Zhang, Simeng Wang, Dandan Chen, Jianqiang Shu, Nannan Chong, Qinglian Wang, Ying Xu. Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathwayDiabetology & Metabolic Syndrome 2024; 16(1) doi: 10.1186/s13098-024-01271-6
2
Meina Zou, Yanrong Chen, Zongji Zheng, Shuyue Sheng, Yijie Jia, Xiangyu Wang, Shijing Ren, Yanling Yang, Xiaomin Li, Wenhui Dong, Meiping Guan, Qian Zhang, Yaoming Xue. High-Salt Attenuates the Efficacy of Dapagliflozin in Tubular Protection by Impairing Fatty Acid Metabolism in Diabetic Kidney DiseaseFrontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.741087
3
Xuhui Chen, Lingli Sun, Dongli Li, Xingfei Lai, Shuai Wen, Ruohong Chen, Zhenbiao Zhang, Qiuhua Li, Shili Sun. Green tea peptides ameliorate diabetic nephropathy by inhibiting the TGF-β/Smad signaling pathway in miceFood & Function 2022; 13(6): 3258 doi: 10.1039/D1FO03615G
4
Yuan Tian, Xiao-min Chen, Xian-ming Liang, Xiao-bin Wu, Chun-meng Yao. SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β1 secretion in type 2 diabetes patients with albuminuria: a randomized clinical trialScientific Reports 2022; 12(1) doi: 10.1038/s41598-022-19988-7
5
Yasemin Korkmaz, Burak Dik. The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic ratsFundamental & Clinical Pharmacology 2024; 38(3): 511 doi: 10.1111/fcp.12975
6
Raysa S. Farias, Rodrigo P. Silva-Aguiar, Douglas E. Teixeira, Carlos P. Gomes, Ana Acacia S. Pinheiro, Diogo B. Peruchetti, Celso Caruso-Neves. Inhibition of SGLT2 co-transporter by dapagliflozin ameliorates tubular proteinuria and tubule-interstitial injury at the early stage of diabetic kidney diseaseEuropean Journal of Pharmacology 2023; 942: 175521 doi: 10.1016/j.ejphar.2023.175521
7
Mohammad Amin Mohammad zadeh Gharabaghi, Mohammad Reza Rezvanfar, Nasser Saeedi, Faezeh Aghajani, Mohammad Alirezaei, Pourya Yarahmadi, Amin Nakhostin-Ansari. Comparison of effects of Empagliflozin and Linagliptin on renal function and glycaemic control: a double-blind, randomized clinical trialClinical Diabetes and Endocrinology 2022; 8(1) doi: 10.1186/s40842-022-00142-1
8
Panagiotis Theofilis, Rigas G. Kalaitzidis. SGLT2 Inhibitors and Kidney Diseases: A Clinical PerspectiveCurrent Medicinal Chemistry 2023; 30(23): 2595 doi: 10.2174/0929867330666221227091943
9
Aqsa Ashfaq, Myriam Meineck, Andrea Pautz, Ebru Arioglu-Inan, Julia Weinmann-Menke, Martin C. Michel. A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathyPharmacology & Therapeutics 2023; 249: 108503 doi: 10.1016/j.pharmthera.2023.108503
10
Qinghe Meng, Julia Ma, Liye Suo, Napat Pruekprasert, Prithi Chakrapani, Robert N. Cooney. Galantamine improves glycemic control and diabetic nephropathy in Leprdb/db miceScientific Reports 2023; 13(1) doi: 10.1038/s41598-023-42665-2
11
Carla B Collares-Buzato, Carolina PF Carvalho. Is type 2 diabetes mellitus another intercellular junction-related disorder?Experimental Biology and Medicine 2022; 247(9): 743 doi: 10.1177/15353702221090464
12
Hager M. Mahmoud, Abdel‐Razik H. Abdel‐Razik, Mahmoud A. Elrehany, Eman M. Othman, Amany A. Bekhit. Modified Citrus Pectin (MCP) Confers a Renoprotective Effect on Early‐Stage Nephropathy in Type‐2 Diabetic MiceChemistry & Biodiversity 2024; 21(7) doi: 10.1002/cbdv.202400104
13
Saurabh Nayak, Vinay Rathore, Joyita Bharati, Kamal Kant Sahu. Extending the ambit of SGLT2 inhibitors beyond diabetes: a review of clinical and preclinical studies on non-diabetic kidney diseaseExpert Review of Clinical Pharmacology 2021; 14(12): 1513 doi: 10.1080/17512433.2021.2028620
14
Xiao-chun Zeng, Yuan Tian, Xian-ming Liang, Xiao-bin Wu, Chun-meng Yao, Xiao-min Chen. SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathwayDiabetology & Metabolic Syndrome 2024; 16(1) doi: 10.1186/s13098-024-01280-5
15
Xin-yu Zhao, Shuang-shuang Li, Ying-xin He, Li-jie Yan, Fu Lv, Qi-meng Liang, Yu-hui Gan, Li-pei Han, Hong-de Xu, Yong-chun Li, Yuan-yuan Qi. SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagyAnnals of the Rheumatic Diseases 2023; 82(10): 1328 doi: 10.1136/ard-2023-224242